Chirag Shah, MD MPH

Dr. Chirag Shah is the Medical Director of Gynecologic Oncology & Pelvic Surgery at the Swedish Cancer Institute, a Clinical Associate Professor at the Washington State University Elson T. Floyd College of Medicine, and a Clinical Associate Professor for the Department of Obstetrics & Gynecology at the University of Washington. Dr. Shah earned his Doctor of Medicine at Indiana University School of Medicine and his Master of Public Health in Epidemiology at the University of Washington. He completed his Obstetrics & Gynecology residency at the University of Washington Medical Center in Seattle, his Galloway Fellowship in Gynecologic Oncology at Memorial Sloan- Kettering Cancer Center in New York, and his Fellowship in Gynecologic Oncology at the University of Washington Medical Center in Seattle. Double board-certified in Obstetrics & Gynecology and Gynecologic Oncology, Dr. Shah provides comprehensive gynecology healthcare, including state-of-the-art treatment options for benign and malignant conditions. Besides clinical care and medical education, Dr. Shah is an active clinical researcher, and his work has been presented at national meetings. He is a fellow of the American College of Obstetricians and Gynecologists and a member of the Society of Gynecologic Oncologists, the Seattle Gynecologic Society, the American Society of Clinical Oncology, the Western Association of Gynecologic Oncologists, the Seattle Gynecologic Society, and the Pacific Coast OB/GYN Society. Dr. Shah is a Past President and a Member of the Board of the Seattle Gynecologic Society. He also previously served on the Society of Gynecologic Oncology Coding Committee and the Clinical Practice Committee.
Financial relationships
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Glaxo Smith KlineTopic:Ovarian/Endometrial CancerDate added:05/28/2025Date updated:05/28/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:PfizerTopic:Cervical CancerDate added:05/28/2025Date updated:05/28/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:AbbvieTopic:Ovarian CancerDate added:05/28/2025Date updated:05/28/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:NateraTopic:Pan TumorDate added:05/28/2025Date updated:05/28/2025